RxDoctor Payments Data

John Siegle, MD

Obstetrics & Gynecology · Ada, OKNPI 1710073044

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $46,783 of the $49,974 with a category attached, or 93.6%. 20 manufacturers reported payments, led by Merck at 54.8% of the total. Reporting peaked in 2019 at $19,714 and has fallen 99.1% since, to $182 in 2025. Among obstetrics & gynecology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,974in general payments, 2019–2025

Across 132 payments — averaging $378.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$27K
  • Organon$22K
  • AbbVie$215
  • Bayer$94
  • Medtronic$76
  • Amgen$67
  • plus $389 from 14 others

What the payments were for

  • Speaking & faculty fees$46,78394%
  • Travel & lodging$1,5263%
  • Food & beverage$1,6653%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,974 in reported general payments places this provider in the 95th percentile of 396 obstetrics & gynecology providers in Oklahoma.

See all obstetrics & gynecology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$10,296
Medicare patients
27
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$12,646
Estradiol98$4,167
ProgesteroneProgesterone, Micronized22$970
Oxybutynin Chloride20$210
Alendronate Sodium19$198
Clobetasol Propionate11$181
Medroxyprogesterone Acetate13$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$21$12,64616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 obstetrics & gynecology providers in Oklahoma.

Other obstetrics & gynecology in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →